[4-A-1] From the electronicization of the attached document (user side) to the next stage
- To that end--
standard of care (medicine), value of medicine, package insert
With the revision of the Pharmaceutical Affairs Law (December 2019), the electronicization of accompanying documents for ethical drugs (August 1, 2021 ) will begin, and barcode labeling will be mandatory from December 1, 2022. This digitization has established a means to obtain up-to-date information on prescription drugs anywhere, without regional or time differences, by registering an application. As the number of media providing information increases, society will want to know more correct information about the importance and value of medical care.
At last year's convention, we received presentations and opinions from the providers of information. At this year's convention, we aim to have pharmacies and hospitals, as users, make presentations on the state of utilization and their requests. The digitization of information is not the end of the process. We need to think about how to develop the next step in the future. Extensive discussions on what is necessary and what must be done to achieve this will begin to spread in Japan as "standards for medical (drug) information" and be shared by healthcare providers. Once the "Drug Information Guidelines (tentative name)" and other guidelines are established, they will be reflected in healthcare policy. In addition, in this project, we would like to discuss RWD and RWE in order to recognize the necessity of data analysis and the importance of secondary use in response to changes and trends in society.
The speed of information dissemination is accelerating. Patients and their families are accessing a great deal of information (on medicines). Moreover, it is beyond the borders of Japan. However, whether this information is correct or not is another matter. We need to think about such issues.
At last year's convention, we received presentations and opinions from the providers of information. At this year's convention, we aim to have pharmacies and hospitals, as users, make presentations on the state of utilization and their requests. The digitization of information is not the end of the process. We need to think about how to develop the next step in the future. Extensive discussions on what is necessary and what must be done to achieve this will begin to spread in Japan as "standards for medical (drug) information" and be shared by healthcare providers. Once the "Drug Information Guidelines (tentative name)" and other guidelines are established, they will be reflected in healthcare policy. In addition, in this project, we would like to discuss RWD and RWE in order to recognize the necessity of data analysis and the importance of secondary use in response to changes and trends in society.
The speed of information dissemination is accelerating. Patients and their families are accessing a great deal of information (on medicines). Moreover, it is beyond the borders of Japan. However, whether this information is correct or not is another matter. We need to think about such issues.